Latest News

Filters

Filter by tags: Radiopharmaceutical Iodine-131 Clear all tag filters

4 news articles found


Rosatom has begun construction of a new plant for the production of medical isotope products at the Karpov Scientific Research Institute of Physics & Chemistry in Obninsk, Kaluga region. The plant will produce a wide range of radiopharmaceuticals including those based on iodine-131, samarium-153, and molybdenum-99 isotopes. It will also develop promising active radiopharmaceuticals based on lutetium-177, actinium-225, radium-223 and other isotopes. Once completed, in 2025, it will be the largest such facility in Europe, Rosatom says. It will operate in accordance with international GMP (good manufacturing practice) standards.

Date: Friday, 27 January 2023
Original article: neimagazine.com/news/newsrosatom-begins-construction-of-radiopharmaceuticals-plant-10546229

The aim is to have production lines operating at the plant in Obninsk by 2025, supplying products for the diagnosis and treatment of patients, including a wide range of cancers. Rosatom says it will ensure Russia's sovereignty in the production of radiopharmaceuticals.

Date: Wednesday, 25 January 2023
Original article: world-nuclear-news.org/Articles/Construction-starts-for-Russian-medical-isotopes-p

Isotop JSC (part of Rusatom Healthcare, Rosatom’s radiation technologies integrator) on 9 June signed a five-year contract with Brazil’s Nuclear and Energy Research Institute (IPEN, part of the National Nuclear Energy Commission, CNEN) to supply medical isotopes lutetium-177 and actinium-225.

Date: Friday, 11 June 2021
Original article: neimagazine.com/news/newsrosatom-to-supply-brazil-with-key-medical-isotopes-8810883

Rusatom Healthcare, part of state nuclear corporation Rosatom, will build Russia’s first radiopharmaceutical plant to meet global GMP good manufacturing practice standards. The new production facility will be in Obninsk at the site of LYa Karpov Scientific Research Institute of Physics & Chemistry (NIFKhl) and will produce drugs for targeted cancer therapy. The design of pharmaceutical production will be carried out by the Central Design and Technological Institute. Pre-design work is planned to be completed this year, for commissioning in 2024  production in early 2025.

Date: Friday, 07 August 2020
Original article: neimagazine.com/news/newsrussia-to-open-radiopharmaceutical-plant-in-obninsk-8064702

Countries

Organisations

Status

No Tags found.